Global Glioma Therapeutics Market Analysis & Trends 2015-2018 & Industry Forecast to 2027 Featuring F.Hoffmann-La Roche, Merck Sharp & Dohme, Mylan, NextSource Biotechnology & Novartis - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 31, 2019--The “Global Glioma Therapeutics Market Analysis & Trends - Industry Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.
The Global Glioma Therapeutics Market is poised to grow strong during the forecast period 2017 to 2027.
Some of the prominent trends that the market is witnessing include Advances in Glioblastoma Multiforme Treatment, Rise in Patient Population and Expedited Drug Discovery Process and Decrease in development of drug cost.
Based on Product, the market is categorized into Small molecules and Biologics.
This industry report analyzes the market estimates and forecasts of all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2015, 2016 revenue estimations are presented for 2017 and forecasts from 2018 till 2027.
The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies for the existing players, new entrants and the future investors.
Key Topics Covered:
1 Market Outline
2 Executive Summary
3 Market Overview 3.1 Current Trends 3.1.1 Advances in Glioblastoma Multiforme Treatment 3.1.2 Rise in Patient Population and Expedited Drug Discovery Process 3.1.3 Decrease in development of drug cost 3.1.4 Growth Opportunities/Investment Opportunities 3.2 Drivers 3.3 Constraints 3.4 Industry Attractiveness
4 Glioma Therapeutics Market, By Product 4.1 Small molecules 4.2 Biologics
5 Glioma Therapeutics Market, By Geography
6 Key Player Activities 6.1 Mergers & Acquisitions 6.2 Partnerships, Joint Ventures, Collaborations and Agreements 6.3 Product Launch & Expansions 6.4 Other Activities
7 Leading CompaniesF.Hoffmann-La Roche Merck Sharp & Dohme Mylan NextSource Biotechnology Novartis
For more information about this report visit https://www.researchandmarkets.com/research/mbj9wt/global_glioma?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190131005571/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Brain Cancer Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/31/2019 10:10 AM/DISC: 01/31/2019 10:10 AM